Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pleased to announce the approval of a significant AUD $6.75 million Research and Development (R&D) Tax Incentive rebate for the financial year ending 30 June 2024. This rebate, provided by the Australian Taxation Office, reflects the Company's R&D activities conducted both locally and internationally, enabling Repayments of Advances from Endpoints Capital. The Australian Government's 43.5% R&D Tax Incentive rebate supports innovation in life sciences, allowing Recce to capture R&D activities worldwide.

CEO James Graham expressed delight in receiving this rebate, emphasizing the Australian Government's support for innovation. This funding enhances Recce's ability to advance R&D initiatives globally, driving the development of cutting-edge anti-infective solutions. By leveraging this rebate, Recce is positioned to make significant advancements in infection treatment on a global scale.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pleased to announce the approval of a significant AUD $6.75 million Research and Development (R&D) Tax Incentive rebate for the financial year ending 30 June 2024. This rebate, provided by the Australian Taxation Office, reflects the Company's R&D activities conducted both locally and internationally, enabling Repayments of Advances from Endpoints Capital. The Australian Government's 43.5% R&D Tax Incentive rebate supports innovation in life sciences, allowing Recce to capture R&D activities worldwide.<br/><br/>CEO James Graham expressed delight in receiving this rebate, emphasizing the Australian Government's support for innovation. This funding enhances Recce's ability to advance R&D initiatives globally, driving the development of cutting-edge anti-infective solutions. By leveraging this rebate, Recce is positioned to make significant advancements in infection treatment on a global scale.<br/><br/>Investors are encouraged to inquire further about this development and its impact on Recce Pharmaceuticals' strategic growth trajectory. This announcement signifies a pivotal milestone in the company's mission to combat antibiotic-resistant superbugs and emerging viral pathogens through its innovative synthetic anti-infectives pipeline.

AUD $6.75m R&D Rebate Approved

Announcement summary